Flora Growth Signs Deal to Supply Medical Cannabis to Germany

Flora's distribution network in Germany has access to and has sold to more than 1,200 pharmacies across the country.

I Stock 2099778939
iStock/Georgiy Datsenko

Flora Growth announced a strategic supply agreement with Blossom Genetics to bring Colombian medical cannabis to the German market. This partnership will introduce two exotic strains, Chemmy Jones and Northern Lights, to Germany, supporting Flora's mission to meet the country's growing demand for high-quality medical cannabis following the legalization of cannabis on April 1, 2024.

Flora's wholly owned subsidiaries have been active in Germany since 2017, obtained the first medical cannabis license in Germany and are responsible for selling the first gram of medical cannabis in the country. Flora also has an EU-GMP facility in the country. Flora's distribution network in Germany has access to and has sold to more than 1,200 pharmacies across the country.

With this agreement, Flora will leverage its expertise in distribution to deliver Chemmy Jones and Northern Light, both known for their potential properties, to Germany's evolving medical cannabis market. The transaction underscores Flora's commitment to scaling operations in Europe, ensuring that German patients have access to some of the world's best cannabis strains.

As part of Flora's broader European strategy, this partnership highlights the growing importance of the German market, which has been a sharp increase in demand for medical cannabis since legalization. Beginning April 1, 2024, patients across Germany have sought new strains for medical use, and Flora is poised to fulfill this need through its agreement Blossom Genetics, starting deliveries in the fourth quarter of 2024.

More in Distribution